Brief: Orchid Pharma Gets ANDA Approval From USFDA For Risedronate Sodium Tablets
14/05/2019 11:46
May 14 (Reuters) - Orchid Pharma Ltd ORCD.NS :
* SAYS GOT ANDA APPROVAL FROM US FDA FOR RISEDRONATE SODIUM
TABLETS
Source text: http://bit.ly/2JfpWGU
Further company coverage: ORCD.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchid Pharma
See all newsBrief: Orchid Pharma Approves Enabling Resolution To Explore Fund Raising Via Equity Or Other Securities
Brief: Orchid Pharma To Consider And Evaluate Various Options For Raising Funds
Brief: Orchid Pharma June-Quarter Consol Profit 25.8 Million Rupees
India's Orchid Pharma jumps on pact to commercialize Exblifep in Russia
Refile: INDIA STOCKS-Indian shares set to open lower as US-Iran tensions lift oil prices